The Effect of Dapagliflozin on the Incidence of Atrial Fibrillation After Coronary Artery Bypass Grafting

The Effect of Dapagliflozin on the Incidence of Atrial Fibrillation After Coronary Artery Bypass Grafting: A Clinical Trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20250302064896N2

Enrollment

110

Registered

2025-06-04

Start date

2025-05-28

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Coronary Artery Bypass Grafting. Condition 2: Atrial fibrillation. Unspecified complication of cardiac and vascular prosthetic device, implant and graft Atrial fibrillation and flutter

Interventions

Intervention 1: Intervention group:. Intervention 2: Control group:.

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Patients undergoing elective Coronary Artery Bypass Grafting (CABG). Patients aged between 18 and 70 years who are candidates for CABG.

Exclusion criteria

Exclusion criteria: Patients with left ventricular (LV) dysfunction Patients with left atrial (LA) enlargement Patients with diabetes mellitus Patients with chronic kidney disease (CKD) and glomerular filtration rate (GFR) below 30 Patients with a history of atrial fibrillation (AF) Patients with chronic obstructive pulmonary disease (COPD) Patients with a history of urinary tract infection (UTI) Patients with liver failure Patients with mitral valve (MV) disease of more than moderate severity

Design outcomes

Primary

Measure	Time frame
Occurrence of atrial fibrillation after coronary artery bypass grafting (CABG) Recording the presence or absence of atrial fibrillation (AF) in patients within 48 to 72 hours postoperatively, based on continuous telemetry monitoring and repeated electrocardiograms (ECG); this outcome is used to evaluate the effect of dapagliflozin in preventing AF as the primary endpoint of the study. Timepoint: It will begin 48 hours before the surgery and continue for 48 to 72 hours postoperatively. Method of measurement: Continuous cardiac rhythm monitoring using hospital telemetry systems and repeated electrocardiograms performed with a standard electrocardiography device to detect and record the occurrence of atrial fibrillation after coronary artery bypass grafting.	—

Measure

Time frame

Occurrence of atrial fibrillation after coronary artery bypass grafting (CABG) Recording the presence or absence of atrial fibrillation (AF) in patients within 48 to 72 hours postoperatively, based on continuous telemetry monitoring and repeated electrocardiograms (ECG); this outcome is used to evaluate the effect of dapagliflozin in preventing AF as the primary endpoint of the study. Timepoint: It will begin 48 hours before the surgery and continue for 48 to 72 hours postoperatively. Method of measurement: Continuous cardiac rhythm monitoring using hospital telemetry systems and repeated electrocardiograms performed with a standard electrocardiography device to detect and record the occurrence of atrial fibrillation after coronary artery bypass grafting.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Javad Mohammad Taghizadeh

Ahvaz University of Medical Sciences

dr.taghizadeh87@gmail.com+98 61 3339 4810

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026